Pharmion Vidaza Phase III Shows First Survival Advantage In Patients With High-Risk Myelodysplastic Syndromes
This article was originally published in The Pink Sheet Daily
Executive Summary
Treatment with Vidaza is associated with 24.4-month median survival compared to 15 months for conventional care.
You may also be interested in...
Celgene Awaits FDA Nod To Relaunch Vidaza With Survival Labeling
Move capitalizes on failure of Eisai’s Dacogen to show a survival benefit in elderly MDS patients.
Celgene Awaits FDA Nod To Relaunch Vidaza With Survival Labeling
Move capitalizes on failure of Eisai’s Dacogen to show a survival benefit in elderly MDS patients.
Vidaza Key To Celgene’s $2.9 Billion Pharmion Purchase
Celgene gains first myelodysplastic syndromes therapy to show survival benefit in high-risk patients, as well as full control of multiple myeloma therapy thalidomide and late-stage candidates.